We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-6.38%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$952M
AUM Growth
+$36.2M
Cap. Flow
+$167M
Cap. Flow %
17.57%
Top 10 Hldgs %
50.62%
Holding
63
New
7
Increased
16
Reduced
13
Closed
4

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$67.2M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$61M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$50M
4
CBIO
Crescent Biopharma
CBIO
+$47.3M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$21M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$55.3M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$20.5M
3
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$19.5M
4
CYTK icon
Cytokinetics
CYTK
+$12.7M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$4.8M

Sector Composition

Rank Sector Weight
1 Healthcare 94.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
26
AnaptysBio
ANAB
$1.57B
$12.4M 1.3%
353,818
+148,553
+72% +$7.07M
AKRO
27
DELISTED
Akero Therapeutics
AKRO
$10.7M 1.13%
471,746
-176,602
-27% -$4.11M
SPRO icon
28
Spero Therapeutics
SPRO
$68.9M
$9.96M 1.05%
939,704
– –
CCXI
29
DELISTED
ChemoCentryx, Inc.
CCXI
$9.59M 1.01%
1,414,515
– –
CRVS icon
30
Corvus Pharmaceuticals
CRVS
$1.11B
$9.17M 0.96%
3,047,155
+272,405
+10% +$1.14M
EPIX
31
DELISTED
ESSA Pharma
EPIX
$8.9M 0.94%
2,640,565
+1,310,865
+99% +$3.24M
GLMD icon
32
Galmed Pharmaceuticals
GLMD
$4.82M
$8.76M 0.92%
10,180
– –
PTGX icon
33
Protagonist Therapeutics
PTGX
$8.7B
$8.2M 0.86%
682,630
-381,172
-36% -$4.8M
PRVL
34
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$8.06M 0.85%
656,483
– –
VSTM icon
35
Verastem
VSTM
$502M
$7.66M 0.8%
527,416
– –
XFOR icon
36
X4 Pharmaceuticals
XFOR
$373M
$7.54M 0.79%
19,782
+432
+2% +$171K
OVID icon
37
Ovid Therapeutics
OVID
$424M
$7.52M 0.79%
2,321,236
-1,262,000
-35% -$2.87M
FWP
38
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$6.61M 0.69%
925,726
-285,714
-24% -$1.9M
MRSN
39
DELISTED
Mersana Therapeutics
MRSN
$6.39M 0.67%
161,676
+61,760
+62% +$4.49M
GNCA
40
DELISTED
Genocea Biosciences, Inc.
GNCA
$6.09M 0.64%
2,100,305
– –
CTIC
41
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$5.77M 0.61%
6,929,690
– –
EIGR
42
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$5.53M 0.58%
17,984
-4,516
-20% -$1.47M
CDTX
43
DELISTED
Cidara Therapeutics
CDTX
$5.36M 0.56%
134,387
+1,742
+1% +$58.6K
FSTX
44
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$4.83M 0.51%
344,710
+19,285
+6% +$318K
BLRX
45
BioLineRX
BLRX
$11.9M
$4.58M 0.48%
43,326
– –
VIRX
46
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$4.46M 0.47%
176,998
-16,443
-9% -$475K
ALPN
47
DELISTED
Alpine Immune Sciences Inc
ALPN
$4.46M 0.47%
1,137,764
-13,953
-1% -$59.9K
GMDA
48
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$4.33M 0.45%
1,000,000
– –
LITS
49
Lite Strategy Inc
LITS
$32.8M
$3.73M 0.39%
111,064
– –
STRO icon
50
Sutro Biopharma
STRO
$408M
$3.13M 0.33%
+34,420
New +$3.48M
1
2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2019 Portfolio in Review

As of Q3 2019, BVF Inc held 63 positions worth $952M, up 4% from $916M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

BVF Inc deployed $167M of net new capital in Q3 2019, opening 7 new positions and adding to 16 existing holdings. Its largest new stake was SpringWorks Therapeutics: 2,844,145 shares worth $61.7M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 90% a quarter earlier.

On the sell side, the largest reduction was Mirati Therapeutics, Inc. Common Stock, an estimated $20.5M trimmed.

  • BVF Inc's largest Q3 2019 buy was SpringWorks Therapeutics: 2,844,145 shares worth $61.7M.
  • BVF Inc added most to Arqule Inc in Q3 2019, an estimated $12.5M increase.
  • BVF Inc's biggest Q3 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $20.5M.
  • BVF Inc fully exited Array Biopharma Inc in Q3 2019, selling an estimated $55.3M.
  • BVF Inc's ten largest holdings make up 51% of its $952M portfolio in Q3 2019.
  • BVF Inc opened 7 new positions and closed 4 in Q3 2019.
  • BVF Inc's portfolio value rose 4% quarter-over-quarter to $952M.

Based on BVF Inc's 13F filing for Q3 2019, filed 14 Nov 2019.